Evaluation of the Effects of Treatment of Psycho-stimulant and Cannabis-dependent Users in Israel

Evaluation of the Effects of Psychological and Pharmacological Treatment of Psycho-stimulant and Cannabis-dependent Users in Kfar Izun in Israel

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01510015

Enrollment

100

Registered

2012-01-13

Start date

2012-01-31

Completion date

2013-11-30

Last updated

2012-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis Dependence, Psychostimulant Dependence

Keywords

cannabis, psychostimulants, psychosis

Brief summary

This study evaluates the effects of psychological and pharmacological treatment of regular users of cannabis and psychostimulants in a treatment center (Kfar Izun) in Israel. The participants will undergo psychological evaluation before and during treatment and follow up at 4 months. Ten participants will undergo brain imaging of the dopamine receptor D2 in order to evaluate the effects of treatment on dopamine turnover in the brain. A control group of psychiatric in-patients undergoing treatment for psychiatric illness with be recruited from Geha Hospital in Israel. It is predicted that successful treatment of regular users of cannabis will be resulted in improvement in anxiety, depression and psychotic symptoms as well as in upregulation of dopamine turnover in participants that will undergo brain imaging.

Detailed description

There is a significant number of cannabis and psychostimulant users that experience psychotic episodes and require psychiatric treatment. This study evaluates the effects of psychological and pharmacological treatment of regular users of cannabis and psychostimulants in a treatment center (Kfar Izun) in Israel. The participants will undergo psychological evaluation before and during treatment and follow up at 4 months. Ten participants will undergo brain imaging of the dopamine receptor D2 using \[I123\] IBZM in Single Photon Emitted Tomography (SPECT) before and after treatment in order to evaluate the effects of treatment on dopamine turnover in the brain. A control group of psychiatric in-patients undergoing treatment for psychiatric illness with be recruited from Geha Hospital in Israel.

Interventions

DRUGRisperidone

variable dose

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to 45 Years

Healthy volunteers

Inclusion criteria

* cannabis dependence with or without history of psychosis.

Exclusion criteria

* pregnant women * under 18 * neurological damage * HIV positive * dependence on other drugs such as heroin * cocaine or alcohol

Design outcomes

Primary

Measure	Time frame	Description
Questionnaire ratings of anxiety, depression and psychotic symptoms	4 months	Questionnaire measures of anxiety (Spielberger) Depression (BDI) and psychotic symptoms (PNAAS) will be used at baseline, during treatment and follow up at 4 months

Secondary

Measure	Time frame	Description
Dopamaine receptor D2 occupancy	At baseline and after 4 months	Measures of dopamine receptor D2 occupancy using \[I123\] IBZM in Single Photon Emitted Tomography (IBZM) will be taken before and after treatment at 4 months.

Countries

Israel

Contacts

Primary ContactAviv M Weinstein, Ph.D

avivweinstein@yahoo.com+97236973536

Backup ContactHedva Shaham, M.D

hedval@gmail.com+97236973536

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026